KR101408653B1 - 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질 - Google Patents

원핵 세포로부터의 재조합 ｎ-글리코실화 단백질 Download PDF

Info

Publication number
KR101408653B1
KR101408653B1 KR1020077028970A KR20077028970A KR101408653B1 KR 101408653 B1 KR101408653 B1 KR 101408653B1 KR 1020077028970 A KR1020077028970 A KR 1020077028970A KR 20077028970 A KR20077028970 A KR 20077028970A KR 101408653 B1 KR101408653 B1 KR 101408653B1
Authority
KR
South Korea
Prior art keywords
protein
prokaryotic organism
organism
glycosylation
glycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020077028970A
Other languages
English (en)
Korean (ko)
Other versions
KR20080048990A (ko
Inventor
마르쿠스 아에비
미하엘 코바리크
우메시 아후자
Original Assignee
에테하 취리히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에테하 취리히 filed Critical 에테하 취리히
Publication of KR20080048990A publication Critical patent/KR20080048990A/ko
Application granted granted Critical
Publication of KR101408653B1 publication Critical patent/KR101408653B1/ko
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020077028970A 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질 Active KR101408653B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05010276 2005-05-11
EP05010276.3 2005-05-11
PCT/EP2006/004397 WO2006119987A2 (en) 2005-05-11 2006-05-10 Recombinant n-glycosylated proteins from procaryotic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147001671A Division KR101524636B1 (ko) 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질

Publications (2)

Publication Number Publication Date
KR20080048990A KR20080048990A (ko) 2008-06-03
KR101408653B1 true KR101408653B1 (ko) 2014-06-17

Family

ID=37396912

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077028970A Active KR101408653B1 (ko) 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질
KR1020147001671A Active KR101524636B1 (ko) 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147001671A Active KR101524636B1 (ko) 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질

Country Status (19)

Country Link
US (3) US8753864B2 (https=)
EP (3) EP2311972B1 (https=)
JP (3) JP5356807B2 (https=)
KR (2) KR101408653B1 (https=)
CN (2) CN101360831B (https=)
AT (1) ATE483027T1 (https=)
AU (1) AU2006245969B8 (https=)
CA (1) CA2607595C (https=)
CY (1) CY1116285T1 (https=)
DE (1) DE602006017207D1 (https=)
DK (2) DK2311972T3 (https=)
ES (3) ES2353814T3 (https=)
HK (1) HK1205193A1 (https=)
HR (1) HRP20150312T1 (https=)
IL (2) IL187293A (https=)
PL (1) PL2311972T3 (https=)
PT (2) PT1888761E (https=)
SI (1) SI2311972T1 (https=)
WO (1) WO2006119987A2 (https=)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
CN107119095B (zh) 2008-01-03 2022-07-05 康乃尔研究基金会有限公司 原核生物中的糖基化蛋白表达
CA2711503A1 (en) * 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
CN101983070B (zh) * 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
PL2411503T3 (pl) * 2009-03-27 2018-01-31 Eidgenoessische Technische Hochschule Zuerich Salmonella enterica prezentująca n-glikan z c. jejuni lub jego pochodne
NO2501406T3 (https=) * 2009-11-19 2018-05-19
PT2545081E (pt) 2010-02-11 2015-05-18 Univ Alberta Compostos de glicano ligados por n
EP3281639B1 (en) * 2010-05-06 2020-11-11 GlaxoSmithKline Biologicals S.A. Capsular gram-positive bacteria bioconjugate vaccines
US20130266604A1 (en) * 2010-09-03 2013-10-10 The Governors of the University of Alberta a non-profit educational institution Peptide containing multiple n-linked glycosylation sequons
US20140336366A1 (en) * 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
EP3508579B1 (en) 2012-11-07 2021-06-30 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
CA2923957C (en) 2013-01-18 2021-08-31 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
CN105228984B (zh) * 2013-03-15 2018-03-23 爱西里斯药物技术有限公司 硝羟喹啉碱加成盐及其用途
RU2671473C2 (ru) 2013-04-05 2018-10-31 Де Гавенерс Оф Де Юниверсити Оф Альберта Вакцина против кампилобактериоза
MX371513B (es) * 2013-10-11 2020-01-31 Glaxosmithkline Biologicals Sa Metodos de modificacion de celulas huespedes.
WO2015124769A1 (en) 2014-02-24 2015-08-27 Glycovaxyn Ag Novel polysaccharide and uses thereof
CA2945542C (en) * 2014-04-17 2024-03-05 Glycovaxyn Ag Modified host cells and uses thereof
WO2016020499A2 (en) 2014-08-08 2016-02-11 Glycovaxyn Ag Modified host cells for use in bioconjugate production
CN107614679B (zh) * 2014-12-30 2026-04-07 葛兰素史密丝克莱恩生物有限公司 用于蛋白糖基化的组合物和方法
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
BR112019015425A2 (pt) * 2017-01-27 2020-05-26 University Of Florida Research Foundation, Incorporated Uma vacina de segurança alimentar para controlar salmonella enterica e reduzir campylobacter em aves domésticas
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
WO2019035916A1 (en) 2017-08-15 2019-02-21 Northwestern University DESIGN OF PROTEIN GLYCOSYLATION SITES BY RAPID EXPRESSION AND CHARACTERIZATION OF N-GLYCOSYLTRANSFERASES
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
WO2019175147A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against intra-abdominal infections
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
WO2019204346A1 (en) 2018-04-16 2019-10-24 Northwestern University METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES
US12098433B2 (en) 2018-08-03 2024-09-24 Northwestern University On demand, portable, cell-free molecular sensing platform
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
CN113646438A (zh) 2019-01-11 2021-11-12 西北大学 在原核生物细胞裂解物中合成生物缀合物疫苗
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
CN115135771A (zh) 2019-10-25 2022-09-30 西北大学 用于富集膜泡和增加糖蛋白产量的无细胞提取物制备方案
EP4461744A3 (en) 2020-01-16 2025-01-08 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
WO2021255684A1 (en) 2020-06-18 2021-12-23 Glaxosmithkline Biologicals Sa Shigella-tetravalent (shigella4v) bioconjugate
WO2021259743A2 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Vaccine
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
KR20250007029A (ko) 2021-01-12 2025-01-13 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
IL307247A (en) 2021-04-01 2023-11-01 Janssen Pharmaceuticals Inc Production of E. Coli O18 bioconjugates
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
CN121646639A (zh) * 2023-08-09 2026-03-10 葛兰素史克生物有限公司 经修饰的蛋白质
WO2025032534A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074687A1 (de) 2001-03-20 2002-09-26 Messer Griesheim Gmbh Verfahren zum regenerieren von schwefelsäure aus schwefelhaltigen stoffen
WO2004013151A2 (en) * 2002-08-01 2004-02-12 National Research Council Of Canada Campylobacter glycans and glycopeptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67786T1 (de) 1984-08-01 1991-10-15 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
JPH09501044A (ja) 1993-05-14 1997-02-04 ジ・アップジョン・カンパニー ＵＤＰ−ＧＡＬＮＡｃ：ポリペプチド、Ｎ−アセチルガラクトサミニルトランスフェラーゼをコードするクローン化されたＤＮＡ
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
EP1399538A4 (en) 1999-03-02 2004-03-24 Human Genome Sciences Inc TECHOLOGICAL MANIPULATION OF INTRACELLULAR SIALIZATION PATHS
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
JP2004528001A (ja) 2000-05-12 2004-09-16 ネオーズ テクノロジーズ， インコーポレイテッド インビトロにおけるフコシル化組換えグリコペプチド
EP1294910B1 (en) 2000-06-30 2008-11-19 VIB vzw Protein glycosylation modification in pichia pastoris
KR101495616B1 (ko) 2002-03-07 2015-02-26 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074687A1 (de) 2001-03-20 2002-09-26 Messer Griesheim Gmbh Verfahren zum regenerieren von schwefelsäure aus schwefelhaltigen stoffen
WO2004013151A2 (en) * 2002-08-01 2004-02-12 National Research Council Of Canada Campylobacter glycans and glycopeptides
WO2004013151A3 (en) 2002-08-01 2004-07-01 Ca Nat Research Council Campylobacter glycans and glycopeptides

Also Published As

Publication number Publication date
CN101360831B (zh) 2013-07-10
EP2853600B1 (en) 2018-09-19
IL226857A0 (en) 2013-07-31
CN101360831A (zh) 2009-02-04
US20140323700A1 (en) 2014-10-30
WO2006119987A2 (en) 2006-11-16
DE602006017207D1 (de) 2010-11-11
IL226857A (en) 2017-08-31
AU2006245969B2 (en) 2011-06-02
AU2006245969B8 (en) 2011-08-25
JP2008539743A (ja) 2008-11-20
JP2012100678A (ja) 2012-05-31
CN103396478A (zh) 2013-11-20
US8753864B2 (en) 2014-06-17
CA2607595A1 (en) 2006-11-16
EP2311972B1 (en) 2015-01-21
JP5687637B2 (ja) 2015-03-18
DK1888761T3 (da) 2010-11-01
ES2535084T3 (es) 2015-05-05
SI2311972T1 (sl) 2015-08-31
EP1888761A2 (en) 2008-02-20
WO2006119987A3 (en) 2007-03-08
KR20080048990A (ko) 2008-06-03
EP2853600A1 (en) 2015-04-01
IL187293A0 (en) 2008-04-13
PL2311972T3 (pl) 2015-08-31
ES2703061T3 (es) 2019-03-06
KR20140019482A (ko) 2014-02-14
US20160326563A1 (en) 2016-11-10
US9551019B2 (en) 2017-01-24
EP1888761B1 (en) 2010-09-29
EP2311972A1 (en) 2011-04-20
HK1205193A1 (en) 2015-12-11
IL187293A (en) 2013-06-27
JP2014042533A (ja) 2014-03-13
US20100062484A1 (en) 2010-03-11
HRP20150312T1 (hr) 2015-07-31
ES2353814T3 (es) 2011-03-07
JP5827303B2 (ja) 2015-12-02
CA2607595C (en) 2018-11-27
HK1156983A1 (en) 2016-11-25
CN103396478B (zh) 2016-09-28
DK2311972T3 (en) 2015-04-27
KR101524636B1 (ko) 2015-06-03
AU2006245969A1 (en) 2006-11-16
ATE483027T1 (de) 2010-10-15
PT1888761E (pt) 2011-01-03
PT2311972E (pt) 2015-05-13
CY1116285T1 (el) 2017-02-08
JP5356807B2 (ja) 2013-12-04
HK1113588A1 (en) 2008-10-10

Similar Documents

Publication Publication Date Title
KR101408653B1 (ko) 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질
US11944675B2 (en) Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
AU2011218682B2 (en) Recombinant N-glycosylated proteins from procaryotic cells
HK1156983B (en) Recombinant n-glycosylated proteins from procaryotic cells
HK1113588B (en) Recombinant n-glycosylated proteins from procaryotic cells
AU2014200938A1 (en) Recombinant n-glycosylated proteins from procaryotic cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110509

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130205

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20131022

Patent event code: PE09021S02D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140121

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140520

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140611

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170330

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190327

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210525

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240527

Start annual number: 11

End annual number: 11